Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,124,904
  • Shares Outstanding, K 46,046
  • Annual Sales, $ 15,000 K
  • Annual Income, $ -84,710 K
  • 60-Month Beta 1.27
  • Price/Sales 78.19
  • Price/Cash Flow N/A
  • Price/Book 8.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.54
  • Number of Estimates 2
  • High Estimate -0.52
  • Low Estimate -0.56
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +15.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.16 +10.27%
on 06/29/20
30.00 -18.57%
on 06/16/20
-5.21 (-17.58%)
since 06/10/20
3-Month
15.03 +62.54%
on 04/13/20
37.41 -34.70%
on 05/21/20
+8.50 (+53.36%)
since 04/09/20
52-Week
6.30 +287.78%
on 08/05/19
37.41 -34.70%
on 05/21/20
+15.93 (+187.41%)
since 07/10/19

Most Recent Stories

More News
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

RCUS : 24.43 (-4.08%)
Is Arcus Biosciences (RCUS) Stock Outpacing Its Medical Peers This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

RCUS : 24.43 (-4.08%)
Gilead's Rating Upgraded on Potential Coronavirus Drug Sales

Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.

GILD : 76.32 (+2.16%)
GSK : 39.91 (-1.14%)
GLPG : 191.77 (-4.63%)
RCUS : 24.43 (-4.08%)
Arcus Biosciences (RCUS) Catches Eye: Stock Jumps 5.4%

Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AKCA : 13.01 (-2.11%)
RCUS : 24.43 (-4.08%)
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

--- Gilead Gains Broad Access to Arcus's Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways -

GILD : 76.32 (+2.16%)
RCUS : 24.43 (-4.08%)
Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus

Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.

RHHBY : 44.2300 (-0.61%)
BMY : 57.43 (-1.17%)
INFI : 0.9721 (-9.99%)
RCUS : 24.43 (-4.08%)
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate...

SURF : 5.77 (+1.76%)
RCUS : 24.43 (-4.08%)
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Misses Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?...

RCUS : 24.43 (-4.08%)
Is Arcus Biosciences (RCUS) Outperforming Other Medical Stocks This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

RCUS : 24.43 (-4.08%)
What Makes Arcus Biosciences, Inc. (RCUS) a Strong Momentum Stock: Buy Now?

Does Arcus Biosciences, Inc. (RCUS) have what it takes to be a top stock pick for momentum investors? Let's find out.

RCUS : 24.43 (-4.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RCUS with:

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

2nd Resistance Point 26.90
1st Resistance Point 25.66
Last Price 24.43
1st Support Level 23.72
2nd Support Level 23.02

See More

52-Week High 37.41
Fibonacci 61.8% 25.53
Last Price 24.43
Fibonacci 50% 21.85
Fibonacci 38.2% 18.18
52-Week Low 6.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar